Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21
Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.
Stocks · News reference
Abeona Therapeutics Activates Cincinnati Children’s As Seventh Qualified Treatment Center For Administration Of ZEVASKYN To Treat Wounds In Patients With Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s as the seventh
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Abeona Therapeutics Q2 2026 Earnings Call Transcript
Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data
Abeona Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Abeona Therapeutics Q2 EPS $(0.35) Misses $(0.23) Estimate, Sales $11.380M Miss $12.239M Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.23) by 52.17 percent. This is a 5.41 percent increase over losses of $(0.37) per share